Pharma stock Axsome Therapeutics Inc (NASDAQ:AXSM) is soaring to all-time highs, up 19% at $177.13 at last glance, after the U.S. Food & Drug Administration (FDA) granted priority review to AXS-05 -- its Alzheimer's disease agitation drug. The news drew analyst praise, with Needham and TD Cowen reiterating "buy" ratings on the stock, and the former lifting its price target to $169 from $154. On track for its largest single-day percentage gain since February, AXSM hit a record peak of $178.99 today. Should t ...